Compare BridgeBio Pharma Inc (BBIO) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Corning Incorporated — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Corning Incorporated trades at $162.35 (market cap $135.89B). The key difference: Corning Incorporated is far larger — about 8.2× BridgeBio Pharma Inc's market cap, and Corning Incorporated pays a 0.71% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GLW | |
|---|---|---|
Market Cap | $16.61B | $135.89B |
Sector | Health | Technology |
52-Week High | $90.17 | $255.79 |
52-Week Low | $47.29 | $64.52 |
Enterprise Value | $18.16B | $142.77B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
GLW trades at $165.69, up 5.41% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $15.63B in 2025, with net income surging to $1.60B. The stock is supported by AI-driven optical demand and analyst optimism, though valuation multiples like a P/E of 76.35 appear elevated. Recent news highlights partnerships with major tech firms and a strategic focus on photonics expansion.
The outlook for GLW is positive, driven by AI infrastructure growth and a $10B photonics goal, but risks include high valuation sensitivity and execution challenges. Analysts project a 16.6% upside to the $193.33 consensus target, with 57% recommending buy. Investors should weigh robust fundamentals against premium pricing and competitive pressures in the semiconductor supply chain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
